Acylamino cyclopropane derivatives

Details Acylamino cyclopropane derivatives Acylamino cyclopropane derivatives

2006-06-06

2006-06-06

Bernhardt, Emily (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S253010, C514S255030, C514S256000, C514S249000, C514S331000, C544S295000, C544S365000, C544S393000, C544S335000, C544S349000, C546S234000

Reexamination Certificate

active

07056922

ABSTRACT:
A compound of the formulawherein D, E, F, G, L, T, W, X, Y, Z, U, A, R1, R2, R3, R4, R5, R6R7are as defined in the specification, pharmaceutical compositions thereof, and methods of use to treat diseases and as D3 receptor modulators.

REFERENCES:
patent: 5872119 (1999-02-01), Wermuth et al.
patent: WO 9851671 (1998-11-01), None
Reynolds, Drugs vol. 51, p. 7-11 (1996).
TenBrink, Annual Reports in Medicinal Chemistry, vol. 29, p. 43-51 (1994).
Romero, Arthur G. et al: “Synthesis of Metabolically Stable Arylpiperazine 5-HTIA Receptor Agonists” Bioorg. Med. Chem. Lett. (1992), 2(12), 1703-6, XP001056751.
Norman M H et al., “Effects of Linking Bridge Modifications on the Antipsychotic Profile of Some Phthalimide and Isoindolinone Derivatives” Journal of Medicinal Chemistry, American Chemical Society, Washington, US, vol. 39, No. 1, 1996, pp. 149-157, XP000982309 ISSN: 0022-2623.
Emilien, Gerard et al: “Dopamine D3 agonists” Expert Opinion on Therapeutic Patents (2001), 11(11), 1713-1728, XP001057496.

Affiliated with

Also associated with

Rating

Acylamino cyclopropane derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Acylamino cyclopropane derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Acylamino cyclopropane derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3694439